Pilot study of the effects on cardiac diastolic function of GC811007, a fructosamine oxidase inhibitor, in patients with Type 2 diabetes and diabetic cardiomyopathy

Trial Profile

Pilot study of the effects on cardiac diastolic function of GC811007, a fructosamine oxidase inhibitor, in patients with Type 2 diabetes and diabetic cardiomyopathy

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Trientine (Primary)
  • Indications Diabetic cardiomyopathy
  • Focus Therapeutic Use
  • Acronyms INFO-CARDIAC
  • Most Recent Events

    • 01 Apr 2009 Results publiahed in Diabetologia.
    • 27 Jan 2009 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top